Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Can Monsanto Company (MON) Regain Its Record Highs?

On Wednesday, Monsanto Company (NYSE:MON) will release its latest quarterly results. Given the importance of agriculture in the world, Monsanto Company (NYSE:MON) has seen its stock rise substantially over the past few years. But it still trails where it was in early 2008, during the height of the commodity boom. Can Monsanto regain all of its lost ground?

genetically modified foods

Monsanto Company (NYSE:MON) makes a wide variety of chemicals and fertilizers for the agricultural industry. But the division with the most promise — and controversy — is its seed business, in which the company has engineered crops with a number of valuable traits in order to adapt to different growing conditions around the world. Let’s take an early look at what’s been happening with Monsanto Company (NYSE:MON) over the past quarter and what we’re likely to see in its quarterly report.

Stats on Monsanto

Analyst EPS Estimate $1.61
Change From Year-Ago EPS (1.2%)
Revenue Estimate $4.42 billion
Change From Year-Ago Revenue 4.8%
Earnings Beats in Past 4 Quarters 3

Source: Yahoo! Finance.

Will Monsanto’s earnings grow this quarter?
Analysts have had mixed views of Monsanto’s earnings prospects in recent months. They’ve reduced their calls for the May quarter by $0.13 per share, but they’ve boosted their full-year fiscal 2013 and 2014 estimates modestly. The stock is essentially unchanged since mid-March, having given up gains from earlier in the quarter.

Monsanto Company (NYSE:MON)’s crop technology is the envy of the industry, and the company has had great success in getting its competitors to agree to cross-licensing dealsE I Du Pont De Nemours And Co (NYSE:DD) and Monsanto settled their joint disputes in March, and Monsanto will receive $1.75 billion over 10 years under the deal they reached. Similarly, The Dow Chemical Company (NYSE:DOW) agreed to trade its Enlist Weed Control System for Monsanto’s Corn Rootworm III technology in April.

Monsanto faces some problems, though, especially in maintaining its relationships with farmers. The Supreme Court decided in May that farmers weren’t allowed to take Monsanto seeds and use them over multiple years without paying the company for them. At the same time, however, the U.S. Department of Agriculture hit both Monsanto Company (NYSE:MON) and The Dow Chemical Company (NYSE:DOW) with denials of their requests to approve crops that would survive various herbicidal applications. Hundreds of thousands of people filed comments or signed petitions against the use of genetically modified organisms, showing the extent of the sentiment against Monsanto.

Indeed, Monsanto’s GMO work could pose a threat to U.S. exports, as Japan and South Korea canceled wheat imports earlier this month when genetically modified wheat was found. With countries around the world imposing restrictions on genetically modified food, Monsanto faces an uphill battle with farmers looking to take advantage of high yields to feed the rest of the world.

In Monsanto’s quarterly report, watch for the company to take a stand on how it plans to handle its public relations in light of the GMO controversy. Long-run results depend on Monsanto Company (NYSE:MON)’s ability to navigate the world markets effectively.

The article Can Monsanto Regain Its Record Highs? originally appeared on and is written by Dan Caplinger.

Fool contributor Dan Caplinger and The Motley Fool have no position in any stocks mentioned. You can follow Dan on Twitter @DanCaplinger.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!